[On hypertension therapy with 2-(2,6-dichlorophenylamino-)2-imidazoline hydrochloride (Catapresan)].
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage; D004357:Drug Synergism; D004983:Ethanolamines / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D007267:Injections; D008134:Long-Term Care; D008297:Male; D009921:Metaproterenol / Q000008:administration & dosage; D008875:Middle Aged; D010627:Phenethylamines / Q000008:administration & dosage; D012118:Resorcinols / Q000008:administration & dosage; D013916:Thrombelastography
D000959:Antihypertensive Agents; D001993:Bronchodilator Agents; D004983:Ethanolamines; D007093:Imidazoles; D010627:Phenethylamines; D012118:Resorcinols; D009921:Metaproterenol
Zur Hypertonietherapie mit 2-(2,6-Dichlorphenylamino-)2-imidazolinhydrochlorid (Catapresan)